|Awarded On||August 20, 2014|
|Title||Targeting p53 in Cancer Through Manipulation of p63 and p73|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Min Gyu Lee|
|Cancer Sites||All Sites|
The p53 tumor suppressor gene is widely mutated in over 50% of human cancers. Over a decade ago, p53 was found to be part of a family of genes known as the p53 family, which includes p63 and p73. Many current therapies for cancer patients and molecular studies on p53 as an effective therapeutic target, focus on p53 solely, ignoring the existence of the other p53 family members. Over the last decade, we have learned that this family of genes acts together to suppress tumorigenesis; therefore, a clear understanding of the cross-talk between the p53 family as a whole is needed to effectively treat cancers with alterations in the p53 family of genes. p53 has been classified as undruggable due to...